TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2108474
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose pion irradiation (total doses from 2720-3420 cGy, fraction sizes from 170 to 205 cGy, treatment times from 4 to 5 weeks)
Study: 2108474
Drug: Accelerated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated treatment with 3280 cGy in 14-22 days
Study: 29542390
Drug: Omega-3 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (300 mg daily, 180 mg EPA and 120 mg DHA)
Study: 29542390
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (200 IU daily)
Study: 27935240
Drug: liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg once daily
Study: 21400790
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists and hydroxyethyl starch solution (130/0.4)
Study: 28821284
Drug: 12-week combined
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week combined aerobic and resistance exercise program supervised by a physiotherapist, plus daily physical activity of at least 30 minutes
Study: 12661246
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy
Study: 8020525
Drug: iomeprol-350 (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol-350 (350 mgI/ml)
Study: 8020525
Drug: iopamidol-370 (370
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopamidol-370 (370 mgI/ml)
Study: 8020525
Drug: iomeprol-400 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: iomeprol-400 (400 mgI/ml)
Study: 2690305
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal gel (first dose: 1 mg, second dose 1 or 2 mg, six hours later)
Study: 2690305
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal gel
Study: 25168164
Drug: Stepwise addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise addition (SWA) of bolus insulin aspart
Study: 25168164
Drug: Full basal-bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full basal-bolus (FBB) therapy
Study: 15977084
Drug: Antimigraine drugs
Normalized name: Corticosteroid derivatives, antimigraine drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimigraine drugs
Study: 7702137
Drug: Blind oral
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind oral intubation
Study: 2746493
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose lorazepam (0.0225 mg/kg)
Study: 1308305
Drug: Diazepam (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.15 mg/kg)
Study: 31371228
Drug: Adjuvant hyperthermic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) followed by routine adjuvant systemic chemotherapy
Study: 30911659
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy only
Study: 23172931
Drug: AM dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM dose (once-daily antihypertensive medications taken in the morning)
Study: 23172931
Drug: PM dose
Normalized name: Allergy AM-PM Dose Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM dose (once-daily antihypertensives taken at bedtime)
Study: 23172931
Drug: Add-on dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Add-on dose (once-daily antihypertensives taken in the morning and an additional antihypertensive medication before bedtime)
Study: 21816199
Drug: 15 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 μg VLP vaccine
Study: 21816199
Drug: 45 μg
Normalized name: tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 μg VLP vaccine
Study: 16690579
Drug: Self-report of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-report of daily living skills using the Health Assessment Questionnaire (HAQ)
Study: 11550740
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment (BT)
Study: 20025554
Drug: Voglibose (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose (0.9 mg daily)
Study: 15946554
Drug: Hepatectomy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1
Study: 12742477
Drug: Sirolimus with
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus with low-dose Prograf
Study: 12742477
Drug: Sirolimus with
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus with full-dose Prograf
Study: 10388978
Drug: Insulin-treated patients
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-treated patients with two or more hypoglycemic episodes
Study: 8840366
Drug: Interferon (IFN)‐α
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN)‐α treatment
Study: 1796238
Drug: Quinine 10
Normalized name: quinine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine 10 mg/kg body weight once daily for 5 days
Study: 6404290
Drug: Ro 15-1788
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 15-1788 200 mg
Study: 17559458
Drug: Intraligamental lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraligamental lignocaine (2% lignocaine solution with adrenaline 1 : 80 000)
Study: 15507811
Drug: Chiropractic or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiropractic or physiotherapy treatment
Study: 9632126
Drug: 15 mmol
Normalized name: dibasic potassium phosphate 15 MMOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mmol Mg daily for 3 months
Study: 9632126
Drug: Increased plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased plasma Mg concentration
Study: 7870633
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of anti-hypertensive therapy
Study: 7870633
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of anti-hypertensive therapy
Study: 20216533
Drug: Antibiotic combination
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic combination therapy (oral amoxicillin 1500 mg/day, tetracycline 1500 mg/day, metronidazole 750 mg/day)
Study: 30121419
Drug: Rivaroxaban treatment
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban treatment
Study: 11821266
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg
Study: 23296694
Drug: Benznidazole 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benznidazole 7.5 mg/kg in a single daily dose for 30 days (Group B)
Study: 21362162
Drug: Ferroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferroquine (400 to 1,600 mg single dose; up to 800 mg repeated dose)
Study: 20021991
Drug: Olanzapine/fluoxetine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine/fluoxetine combination (OFC)
Study: 12087932
Drug: Patch subgroup
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch subgroup (EP)
Study: 12087932
Drug: Patch subgroup
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch subgroup (VC)
Study: 12087932
Drug: Gel subgroup
Normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gel subgroup (VC)
Study: 2014947
Drug: Propranolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol plus Is‐5‐Mn (40 mg twice a day)
Study: 6185788
Drug: Medroxalol (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxalol (100-400 mg twice daily)
Study: 6185788
Drug: Medroxalol +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medroxalol + Hydrochlorothiazide (12.5 mg twice daily)
Study: 19666658
Drug: Sevelamer hydrochloride
Normalized name: Sevelamer Hydrochloride
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer hydrochloride tablets
Study: 10330635
Drug: Topical eyedrop
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical eyedrop anesthesia
Study: 8545141
Drug: Capsaicin cream
Normalized name: CAPSAICIN 0.1 g in 100 g TOPICAL CREAM [Capsaicin Cream]
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin cream (0.075%) applied 4 times a day
Study: 6280052
Drug: Placebo (polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (polyethylene glycol ointment)
Study: 20683071
Drug: Lidocaine nasal
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine nasal spray
Study: 29231321
Drug: Acupuncture-moxibustion periodic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-moxibustion periodic therapy
Study: 26212400
Drug: Rehabilitation Intensity
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rehabilitation Intensity of Therapy Scale
Study: 19060263
Drug: Initial medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial medicine or surgery
Study: 16856702
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group training (10 daily sessions for 2 weeks, 3 series of 10 repetitions of flexi‐extension of the foot against an elastic band)
Study: 15459610
Drug: Nicorandil (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (4 mg as a bolus injection followed by constant infusion at 8 mg/hour for 24 hours)
Study: 3169754
Drug: Pivampicillin (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin (700 mg twice a day for 7 days)
Study: 3169754
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg twice a day for 7 days)
Study: 28677416
Drug: Open-loop using
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-loop using sensor-augmented pump therapy (open-loop SAP)
Study: 12644414
Drug: Lactate in
Normalized name: lactate Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate in the prime solution
Study: 12644414
Drug: Lactate free
Normalized name: Lactate free hemofiltration solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate free prime solution
Study: 26156073
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg once daily, titrated based on tolerability)
Study: 24447434
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic treatment (observation)
Study: 23145755
Drug: Bupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 15 mg 0.5% (group 1)
Study: 23145755
Drug: Levobupivacaine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 15 mg 0.5% (group 2)
Study: 28931055
Drug: Normothermic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermic treatment
Study: 29643159
Drug: Multivitamin supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplements containing 150 µg iodine
Study: 21432621
Drug: Generic tamsulosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic tamsulosin sustained-release tablets (Prostam(®))
Study: 16871060
Drug: Remifentanil (0-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0-15 ng/ml) and sevoflurane (0-6 vol%)
Study: 16871060
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 0.75 vol% sevoflurane and 6.2 ng/ml remifentanil
Study: 14680725
Drug: 40 mg/day
Normalized name: cabozantinib s-malate 140 mg/day (80 mg x 1-20 mg x 3/day) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day quinapril for 8 weeks
Study: 10870853
Drug: 60 mcg
Normalized name: Aranesp 60 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mcg PGE1 daily given IV in 250 mL saline over a period of 2 hours (21 patients)
Study: 10870853
Drug: Placebo (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (250 mL saline, 21 patients)
Study: 25038064
Drug: MIRT Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIRT Group (two 28-day multidisciplinary intensive rehabilitation treatments at 1-year interval)
Study: 25038064
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (only drug)
Study: 18497611
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia with intravenous morphine
Study: 17361522
Drug: Compound Glycyrrhizin
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Glycyrrhizin Injection (CGI)
Study: 26277872
Drug: Dexmedetomidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (loading dose of 1.0 μg/kg infused over 10 minutes, maintenance dose of 0.4 μg/kg per hour for 6 hours)
Study: 23912692
Drug: Gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine alone (1,000 mg m(‐2))
Study: 23912692
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus cisplatin (G + C) (1,000 mg m(‐2) gemcitabine and 25 mg m(‐2) cisplatin)
Study: 20206795
Drug: Ticlopidine 250
Normalized name: ticlopidine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine 250 mg alone
Study: 7708953
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose distributions assessment in a separate group of 37 women
Study: 3371023
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg iv every 6 h
Study: 3371023
Drug: 0.75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg/kg iv every 6 h
Study: 1984813
Drug: Tetrahydroaminoacridine (THA)
Normalized name: Tetrahydroaminoacridine
DrugBank: Tacrine (DB00382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrahydroaminoacridine (THA) 50 to 100 mg daily
Study: 6872413
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg amrinone
Study: 27009515
Drug: Ranibizumab 'intensive'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 'intensive' treatment (complete resolution of IRF and SRF)
Study: 27009515
Drug: Ranibizumab 'relaxed'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 'relaxed' treatment (resolution of IRF or >200 μm SRF only at foveal centre)
Study: 27009515
Drug: Ranibizumab 'intensive'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 'intensive' treatment
Study: 27009515
Drug: Ranibizumab 'relaxed'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 'relaxed' treatment
Study: 20298591
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg SC enoxaparin
Study: 20298591
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg SC enoxaparin
Study: 20298591
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg SC enoxaparin
Study: 12459658
Drug: Perflubron emulsion
Normalized name: PERFLUBRON
DrugBank: Perflubron (DB05791)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perflubron emulsion (1.8 g/kg, with an additional 0.9 g/kg dose if hemoglobin < 6.5 g/dl)
Study: 20306820
Drug: Intravenous montelukast,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous montelukast, 5.25 mg
Study: 15951475
Drug: Conventional dipyridamole
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional dipyridamole tablets (immediate-release)
Study: 8273981
Drug: Aspirin 2600
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 2600 mg/d
Study: 8273981
Drug: Aspirin 3
Normalized name: aspirin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 3 mg/d
Study: 8273981
Drug: Aspirin 10
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 10 mg/d
Study: 27789385
Drug: Nocebo suggestions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocebo suggestions (suggestions of pain increase with nocebo cream)
Study: 27789385
Drug: Placebo suggestions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suggestions (suggestions of pain decrease with placebo cream)
Study: 27789385
Drug: Natural history
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural history group (no treatment)
Study: 16492702
Drug: Micronized fenofibrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized fenofibrate (267 mg/d)
Study: 8829419
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 5 mg (10 patients)
Study: 8829419
Drug: Subcutaneous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous morphine 5 mg (10 patients)
Study: 1625092
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of hGH plus oxandrolone
Study: 1625092
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment with hGH (both alone and in combination with oxandrolone)
Study: 6548095
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of methohexitone (5 mg/kg)
Study: 6548095
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of methohexitone (25 mg/kg)
Study: 6548095
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of methohexitone (2 mg/kg)
Study: 6548095
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of pharmacokinetics in children vs adults
Study: 30316811
Drug: Daily Undulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Undulating Periodization (NLP)
Study: 25319729
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day aqueous saffron extract orally
Study: 23007147
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 8 mg/m² (day 1) and Vinorelbine (VNR) 25 mg/m² (days 1 and 8) every 4 weeks for up to 6 cycles
Study: 17445831
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR 150 mg/day
Study: 15905675
Drug: TMC114/ritonavir (RTV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC114/ritonavir (RTV) (300/100 mg or 600/100 mg twice daily, or 900/100 mg once daily)
Study: 12506950
Drug: Fluconazole suspension
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole suspension 3 mg/kg in a single daily dose for 7 days
Study: 12506950
Drug: Nystatin oral
Normalized name: nystatin Oral Tablet
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin oral suspension four times a day for 10 days
Study: 2705441
Drug: Subcutaneous DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous DDAVP
Study: 2705441
Drug: Intravenous DDAVP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous DDAVP
Study: 335794
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of beta-receptor blocker and hydralazine (regimen B)
Study: 11441208
Drug: High-dose acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose acetaminophen (1000 mg)
Study: 11441208
Drug: Low-dose acetaminophen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose acetaminophen (500 mg)
Study: 8332152
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment with ceftriaxone (50 mg/kg body weight, initial dose followed by a second dose 24 hours later)
Study: 8332152
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (ceftriaxone as directed by physicians)
Study: 30882476
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (crystalloid)
Study: 21246578
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish treatment
Study: 17349686
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri ATCC 55730 (1 x 10(8) colony forming units) daily from gestational week 36 until delivery and continued from birth until 12 months of age.
Study: 17349686
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (not specified dosage or duration).
Study: 12960597
Drug: Follow-up 201Tl‐chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Follow-up 201Tl‐chloride scintigraphy after chemotherapy
Study: 10824635
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion after pretreatment with nadolol or propranolol
Study: 10824635
Drug: Propranolol (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (doses < or =7.5 mg)